Cytos Biotechnology AG

EQS-Adhoc: Cytos Biotechnology AG: Invitation for an Extraordinary Shareholders' Meeting

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM
Cytos Biotechnology AG: Invitation for an Extraordinary Shareholders'

19.02.2015 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.


Cytos Biotechnology Ltd. invites for an Extraordinary Shareholders' Meeting

Schlieren (Zurich), Switzerland, February 19, 2015 - Cytos Biotechnology
Ltd ("Cytos" or "the Company"), announced today that an Extraordinary
Shareholders' Meeting will take place on Monday, March 16, 2015 at 10 a.m.
at Cytos' offices in Schlieren/Zurich (Switzerland).

At this meeting, shareholders will be invited to approve the share capital
increase which is needed to create the shares for the conversion of the
convertible bonds into equity. Further, the conditional and authorized
capital shall be amended.

The formal invitation to the meeting will be sent out within the next few
days and can also be downloaded on the following website:

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or

End of ad hoc announcement

Additional features:

Document title: Cytos_150219_EGM_Invitation


19.02.2015 News transmitted by EQS Schweiz AG. - news

The issuer is responsible for the contents of the release.


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Regulated Unofficial Market in Berlin, Munich, Stuttgart;
             Open Market in Frankfurt ; SIX

End of News    EQS Group News-Service
324605 19.02.2015

Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: